Jia, Bailing
Thompson, Hamishi A.
Barndt, Robert B.
Chiu, Yi-Lin
Lee, Mon-Juan
Lee, See-Chi
Wang, Jehng-Kang
Tang, Hung-Jen
Lin, Chen-Yong http://orcid.org/0000-0002-6391-2571
Johnson, Michael D.
Funding for this research was provided by:
National Cancer Institute (RO1 CA 123223, RO1 CA 123223)
Ministry of National Defense Medical Affairs Bureau, Taiwan (MAB-108-079)
Chi Mei Medical Center (CMNDMC10705, CMNDMC10813)
Article History
Received: 25 June 2020
Accepted: 5 August 2020
First Online: 10 August 2020
Compliance with ethical standards
:
: CYL is an inventor on US patents #6,077,938 (Title: Monoclonal antibody to an 80-kDa protease) and #6,677,377 (Title: Structure based discovery of inhibitors of matriptase for the cancer diagnosis and therapy by detection and inhibition of matriptase activity) and MDJ and CYL are inventors on US patent #7,355,015 (Title: Matriptase, a serine protease and its applications). This does not alter our adherence to PLOS ONE policies on sharing data and materials.fficial views of the National Cancer Institute or the National Institutes of Health.